Patheon ops 'transformation' aligns with Q4 losses

Contract manufacturer Patheon is "successfully executing on [its] transformation," says CEO Jim Mullen. "In the locations where we have rolled out our operational excellence programs, we have already realized enhanced capacity, decreased cycle times and improved efficiency," he says in a recent financial filing that reported a fourth-quarter loss of $5.4 million--three times that of the same quarter last year. "Key internal performance metrics are improving." Release | Story

Suggested Articles

A biotech that worked with a nutritional products maker on the API for its clinical-stage radiation drug, is buying all of the manufacturing know-how.

Merck KGaA is selling a manufacturing site and its Allergopharma allergy drug business as it focuses on newer meds.

In a first, the FDA and Indian oversight agencies worked together to block illegal drugs from entering the U.S.